Taysha Gene Therapies Inc (TSHA)

Jan 3, 2025, 8:00 AM EST - 14 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 14, 2024, 8:25 AM EST - 2 months ago

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

AAP

Nov 13, 2024, 10:48 PM EST - 2 months ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 2 months ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:00 AM EDT - 3 months ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Oct 14, 2024, 12:55 AM EDT - 3 months ago

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Aug 12, 2024, 12:08 PM EDT - 5 months ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:01 AM EDT - 5 months ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 26, 2024, 9:14 AM EDT - 7 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 26, 2024, 7:36 AM EDT - 7 months ago

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GIS

Jun 25, 2024, 6:34 PM EDT - 7 months ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 18, 2024, 11:42 AM EDT - 7 months ago

What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 7:30 AM EDT - 7 months ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 12, 2024, 7:00 AM EDT - 7 months ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

May 15, 2024, 4:55 AM EDT - 8 months ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:01 PM EDT - 8 months ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 9 months ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 2, 2024, 8:00 AM EDT - 9 months ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Mar 20, 2024, 12:30 PM EDT - 10 months ago

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 19, 2024, 9:04 PM EDT - 10 months ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:01 PM EDT - 10 months ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 14, 2024, 4:26 PM EDT - 11 months ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Feb 29, 2024, 8:00 AM EST - 11 months ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 15, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Jan 22, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 10, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Dec 19, 2023, 7:30 AM EST - 1 year ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Nov 29, 2023, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Nov 14, 2023, 9:53 PM EST - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:08 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 7, 2023, 8:00 AM EST - 1 year ago

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Nov 3, 2023, 7:41 PM EDT - 1 year ago

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Sep 19, 2023, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

Aug 24, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Aug 21, 2023, 11:28 AM EDT - 1 year ago

GordonMD® Invests in Private Placement for Taysha Gene Therapies

Aug 17, 2023, 6:42 PM EDT - 1 year ago

Taysha Gene Therapies: Rett Syndrome Data Makes This A Must Watch

Aug 14, 2023, 7:02 AM EDT - 1 year ago

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results

Aug 14, 2023, 7:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces $150 Million Private Placement Financing

Jul 31, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Jun 28, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Jun 15, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

May 19, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 11, 2023, 11:13 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11